COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments

Ouédraogo, Dieu-Donné; Tiendrébéogo, W. Joëlle S.; Kaboré, Fulgence; Ntsiba, H

doi:10.1007/s10067-020-05189-y

Cited by 35 publications

(23 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IAs do not seem to be a risk factor for a severe form of COVID-19 despite the immunosuppressive drugs. In the meantime, studies are not yet sufficient to reach to safe conclusions for this topic [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience

et al. 2021

View full text Add to dashboard Cite

To examine whether patients with inflammatory arthritis (IA) treated with conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) and/or biologic (b) DMARDs, could be affected from SARS-CoV-2 infection and to explore the COVID-19 disease course and outcome in this population. This is a prospective observational study. During the period February–December 2020, 443 patients with IA who were followed-up in the outpatient arthritis clinic were investigated. All patients were receiving cs and/or bDMARDs. During follow-up, the clinical, laboratory findings, comorbidities and drug side effects were all recorded and the treatment was adjusted or changed according to clinical manifestations and patient’s needs. There were 251 patients with rheumatoid arthritis (RA), 101 with psoriatic arthritis (PsA) and 91 with ankylosing spondylitis (AS). We identified 32 patients who contracted COVID-19 (17 RA, 8 PsA, 7 AS). All were in remission and all drugs were discontinued. They presented mild COVID-19 symptoms, expressed mainly with systemic manifestations and sore throat, while six presented olfactory dysfunction and gastrointestinal disturbances, and all of them had a favorable disease course. However, three patients were admitted to the hospital, two of them with respiratory symptoms and pneumonia and were treated appropriately with excellent clinical response and outcome. Patients with IA treated with cs and/or bDMARDs have almost the same disease course with the general population when contract COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Since the advent of COVID-19, one of the concerns of rheumatologists has been the risk of intensive care unit admission and excess mortality in patients with chronic inflammatory rheumatic disease [ 6 – 8 ]. Few series have been published [ 9 – 12 ].…”

Section: Discussionmentioning

confidence: 99%

Case Series of Chronic Inflammatory Rheumatic Disease Patients Infected by Coronavirus Disease 2019 (COVID-19)

Tiendrébéogo¹,

Kaboré²,

Diendéré³

et al. 2020

Case Reports in Rheumatology

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a viral infection that appeared in December 2019. The risk of infection seems to be increased in chronic inflammatory rheumatic diseases due to both immune disturbances related to the disease and treatment. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Among these patients, 3 had rheumatoid arthritis and 2 had systemic lupus erythematosus. Patients’ age ranged between 38 and 63 years. Only one patient (SLE) had a severe subtype of COVID-19. All the patients were cured of COVID-19 and were subsequently discharged.

show abstract

“…Our patients were all clinically symptomatic at COVID-19 and the notion of contagion was found in a patient with several close family members confirmed positive for coronavirus. This situation therefore represents a predilection for opportunistic diseases for patients who suffer from systemic disease and are undergoing immunosuppressive treatment [ 10 ]. The existence of RA and SDS in the two patients associated with COVID-19 infection appears to be a vicious circle since RA and SDS are all systemic inflammatory diseases in the same way as COVID-19 viral aggression.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 infection during autoimmune disease: study of 2 cases in Republic of Guinea

Condé¹,

Atakla²,

Garba³

et al. 2020

Pan Afr Med J

View full text Add to dashboard Cite

Introduction Coronavirus is a virus that can target the respiratory, musculoskeletal systems with a cascade of inflammatory processes. The objective of this work is to establish the link between autoimmune diseases and a COVID-19 infection in Guinea. Methods Retrospective patient data were obtained from medical records. Informed consent was obtained under the direction of the national health security agency (ANSS). Results We report the case of two patients aged 52 and 64 years respectively, known to have rheumatoid arthritis (RA) and systemic scleroderma (SDS) admitted with clinical signs suggesting underlying infection with COVID-19. They were tested with RT-PCR, which was positive within hours. Conclusion In view of the rapid clinical worsening of patients with COVID-19 infection and autoimmune diseases, increased surveillance should be undertaken with abstinence of any factors that might weaken the immunity of these patients.

show abstract

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments

Cited by 35 publications

References 51 publications

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience

Case Series of Chronic Inflammatory Rheumatic Disease Patients Infected by Coronavirus Disease 2019 (COVID-19)

COVID-19 infection during autoimmune disease: study of 2 cases in Republic of Guinea

Contact Info

Product

Resources

About